Press Releases

WASHINGTON, Sept. 19 – In a major bipartisan vote, the Senate Committee on Health, Education, Labor, and Pensions (HELP) today held Steward Health Care CEO Dr. Ralph de la Torre in civil and criminal contempt for his failure to comply with the committee’s subpoena and absence from last week’s hearing.  This is the first time in modern American history that the HELP

WASHINGTON, Sept. 19 – In a major bipartisan vote, the Senate Committee on Health, Education, Labor, and Pensions (HELP) today held Steward Health Care CEO Dr. Ralph de la Torre in civil and criminal contempt for his failure to comply with the committee’s subpoena and absence from last week’s hearing. This is the first time in modern American history that the HELP

WASHINGTON, Sept. 18 — Sen. Bernie Sanders (I-Vt.) delivered a speech on the floor of the United States Senate to discuss his intention to next week file Joint Resolutions of Disapproval (JRD) that would block the sale of more than $20 billion in offensive U.S. weaponry to Israel. The JRD is the only mechanism available to Congress to prevent an arms

This afternoon, Sanders will deliver speech on the floor of the Senate on the JRD WASHINGTON, Sept. 18 — Sen. Bernie Sanders (I-Vt.) today announced his intention to next week file Joint Resolutions of Disapproval (JRD) that would block the sale of offensive U.S. weaponry to Israel. The JRD is the only mechanism available to Congress to prevent an arms sale

Dr. Ralph de la Torre failed to comply with Congressional Subpoena WASHINGTON, Sept. 18 – In light of Steward CEO Dr. Ralph de la Torre’s failure to comply with the committee’s subpoena and absence from last week’s hearing, the Senate HELP Committee will vote this Thursday to adopt two resolutions: one for civil enforcement and another for certification to the

WASHINGTON, Sept. 17 – Ahead of next week’s hearing with Novo Nordisk CEO Lars Jørgensen, Sen. Bernie Sanders (I-Vt.), Chairman of the Senate Health, Education, Labor, and Pensions Committee (HELP), today announced that CEOs of major generic pharmaceutical companies are willing to sell Ozempic to Americans for less than $100 per month at a profit. Novo Nordisk currently charges Americans with